Research Policy 2020

Unpacking the effects of adverse regulatory events: Evidence from pharmaceutical relabeling

Matthew J. Higgins¹; Xin Yan²; Chirantan Chatterjee^3,4

¹ University of Utah, NBER & Max Planck Institute for Innovation and Competition, Cambridge, MA, USA · ² Emory University · ³ Hoover Institution · ⁴ Indian Institute of Management Ahmedabad

Abstract

Highlights • Estimates a decline in demand and firm performance from negative regulatory shocks.• Quantifies the loss to the firm using an event study.• Estimates the losses attributable to declines in future innovation.• Supports the view that quicker drug access today may mean less innovation tomorrow.

DOI

10.1016/j.respol.2020.104126

Sources

semanticscholar openalex

Cite

APA 7 MLA 9 Chicago (author–date) Harvard Elsevier Harvard (JFE, JBF…) The Accounting Review Academy of Management American Marketing Association INFORMS (Management Science) Copy citation Copied ✓